HistoSonics is shopping for a potential buyer of its approach to destroying liver tumors with focused sound waves, according ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 ...

To REMS, or not to REMS. That, apparently, was the question for Cytokinetics, which has seen any potential approval for its ...

Pliant Therapeutics will be cutting 45% of staffers as part of a “strategic restructuring of its workforce," the biotech ...

Scholar Rock is shaking up its executive team as it prepares to enter the commercial arena with the expected launch of spinal ...

Tim Friede began willingly injecting himself with escalating doses of venom from 16 snake species. | Eighteen years ago, Tim Friede began willingly injecting himself with escalating doses of venom ...